Parkside Financial Bank & Trust Acquires 759 Shares of Becton, Dickinson and Company $BDX

Parkside Financial Bank & Trust grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 64.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,943 shares of the medical instruments supplier’s stock after buying an additional 759 shares during the period. Parkside Financial Bank & Trust’s holdings in Becton, Dickinson and Company were worth $335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of BDX. Aviva PLC lifted its stake in Becton, Dickinson and Company by 6.0% in the 2nd quarter. Aviva PLC now owns 214,493 shares of the medical instruments supplier’s stock worth $36,946,000 after purchasing an additional 12,175 shares in the last quarter. Prospera Financial Services Inc lifted its position in shares of Becton, Dickinson and Company by 40.1% in the second quarter. Prospera Financial Services Inc now owns 5,936 shares of the medical instruments supplier’s stock worth $1,024,000 after buying an additional 1,699 shares in the last quarter. AGF Management Ltd. boosted its stake in Becton, Dickinson and Company by 29.5% during the second quarter. AGF Management Ltd. now owns 21,940 shares of the medical instruments supplier’s stock valued at $3,779,000 after buying an additional 5,004 shares during the last quarter. True Wealth Design LLC boosted its stake in Becton, Dickinson and Company by 166.7% during the second quarter. True Wealth Design LLC now owns 248 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 155 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after buying an additional 3,268,478 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,249 shares of company stock valued at $231,358 in the last ninety days. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BDX shares. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Royal Bank Of Canada decreased their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a report on Friday. Finally, Piper Sandler dropped their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $203.27.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $177.88 on Monday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The firm has a market cap of $50.99 billion, a price-to-earnings ratio of 31.99, a PEG ratio of 1.42 and a beta of 0.25. The business’s fifty day simple moving average is $186.77 and its two-hundred day simple moving average is $182.15. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 71.36%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.